整理卡格净列说明书_附件1

合集下载

恩列格净片说明书

恩列格净片说明书

恩列格净片说明书1. 产品介绍恩列格净片是一种针对皮肤问题的药膜贴片。

它采用了先进的技术,通过渗透和吸附作用,有效清除皮肤表面的污垢和杂质,改善肌肤质量,使皮肤更加健康和光滑。

2. 使用方法步骤1:准备工作在使用恩列格净片前,请确保脸部已经清洁干净,并且没有任何化妆品残留。

步骤2:取出净片从包装袋中取出一张恩列格净片。

每张净片都是独立包装的,确保卫生安全。

步骤3:粘贴净片将恩列格净片轻轻粘贴在需要处理的部位上。

可以根据个人需求剪裁合适大小的净片。

确保净片与皮肤充分接触,并且不会滑落。

步骤4:按摩使用指尖轻轻按摩净片,帮助其更好地吸附污垢和杂质。

按摩时间可以根据个人需要,一般建议约5-10分钟。

步骤5:取下净片完成按摩后,轻轻撕下净片,然后用清水洗净皮肤。

注意不要过度拉扯皮肤,以免造成刺激。

步骤6:保养使用恩列格净片后,可以继续进行日常的护肤步骤,如涂抹乳液或面霜等。

这样可以进一步滋润和保护皮肤。

3. 主要成分恩列格净片采用了多种有效成分,包括:•活性炭:具有吸附作用,能够有效去除皮肤表面的污垢和杂质。

•薄荷提取物:具有清凉舒缓的作用,能够缓解皮肤不适感。

•水解胶原蛋白:富含胶原蛋白的精华能够滋养和修复皮肤。

这些成分经过科学配比和严格筛选,在使用时不会对皮肤造成任何负面影响。

4. 注意事项•请避免使用在受伤、溃疡或其他异常皮肤部位。

•如出现皮肤不适或过敏,请立即停止使用并咨询医生。

•请将恩列格净片放置在干燥阴凉的地方,避免阳光直射。

•请勿将恩列格净片吞食或接触到眼睛。

5. 效果评估经过多次临床测试和用户反馈,恩列格净片在改善皮肤质量方面表现出色。

使用者普遍反映,恩列格净片能够清除皮肤上的污垢和杂质,使皮肤更加光滑和细腻。

长期使用还可以改善肌肤弹性和亮度。

6. 常见问题解答Q1: 恩列格净片适合哪种类型的皮肤使用?A1: 恩列格净片适用于各种类型的皮肤,包括油性、干性、混合性等。

它不会造成任何刺激或干扰正常的皮肤功能。

达格列净片 FARXIGA (dapagliflozin) FDA药品说明书翻译

达格列净片 FARXIGA (dapagliflozin) FDA药品说明书翻译

FULL PRESCRIBING INFORMATION1 INDICATIONS AND USAGE 适应症和用途FARXIGA (dapagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14)].本药用于配合饮食控制和运动改善2型糖尿病患者的血糖控制。

1.1 Limitation of Use 使用限制FARXIGA is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.本药不适用于1型糖尿病或糖尿病酮症酸中毒患者。

2 DOSAGE AND ADMINISTRATION 用法用量2.1 Recommended Dosing 推荐剂量The recommended starting dose of FARXIGA is 5 mg once daily, taken in the morning, with or without food. In patients tolerating FARXIGA 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily.推荐起始剂量为一次5mg,一日1次,早晨服用,可与或不与食物同服。

对本药一次5mg,一日1次剂量耐受且须更多血糖扩指着,可增至一次10mg,一日1次。

In patients with volume depletion, correcting this condition prior to initiation of FARXIGA is recommended [see Warnings and Precautions (5.1), Use in Specific Populations (8.5, 8.6), and Patient Counseling Information (17)].血容量减少患者,推荐用药前应先纠正血容量减少。

恩列格净片说明书

恩列格净片说明书

恩列格净片说明书首部内容:恩列格净片说明书引言:恩列格净片是一种常见的药物,被广泛用于治疗各种疾病和症状。

本说明书将详细介绍恩列格净片的药物成分、用途、剂量、注意事项等信息,以帮助患者正确使用本药物并避免不必要的风险。

一、药物成分:恩列格净片的主要成分为X物质和Y物质。

X物质具有抗炎作用,可以有效缓解疼痛和红肿;Y物质则具有抗菌作用,能够抑制细菌和病毒的生长。

这两种成分的协同作用使得恩列格净片成为一种非常有效的药物。

二、适用症:恩列格净片适用于治疗多种疾病和症状,包括但不限于以下方面:1. 感冒症状:如流鼻涕、咳嗽、喉咙痛等。

2. 发热状况:如高热、低热等。

3. 炎症反应:如关节炎、扁桃体炎等。

4. 细菌感染:如皮肤感染、尿路感染等。

三、使用方法:1. 用法:口服,建议饭后服用,以提高药效。

2. 剂量:成人每次口服1片,每日2次;儿童剂量请咨询医生。

3. 服用时间:按照医生或药剂师的指示进行规定疗程的用药。

4. 注意事项:饮食清淡,避免食用辛辣、油腻食物;避免与其他药物同时使用,以免发生不良反应。

四、不良反应:恩列格净片在正常剂量下通常是安全有效的,但仍可能出现一些不良反应,包括但不限于以下症状:1. 胃部不适:如恶心、呕吐等。

2. 过敏反应:如皮疹、瘙痒、面部肿胀等。

3. 肠胃功能异常:如腹泻、便秘等。

请在使用药物过程中密切关注身体状况,如出现异常症状,请及时就医。

五、注意事项:1. 孕妇、哺乳期妇女、儿童应在医生指导下使用。

2. 对恩列格净片成分过敏者禁用,请提前了解药物成分并遵循医生的建议。

3. 使用期间注意饮食卫生,避免感染和交叉感染。

4. 若出现过敏反应或不良症状,请立即停药并咨询医生。

六、贮藏:请将恩列格净片放置在阴凉、干燥处,避免阳光直射和潮湿环境。

结语:恩列格净片是一种安全有效的药物,适用于多种疾病和症状的治疗。

在使用时,请仔细阅读本说明书并遵循医生的建议,如有任何问题或不良反应,请及时告知医生。

ColiComplete 产品说明书

ColiComplete 产品说明书

Page 1 of 2 ColiComplete ®AOAC Official Method 992.30General DescriptionColiComplete ® contains 5-bromo-4-chloro-3-indolyl-ß-Dgalactopyranoside (X-Gal) and 4-methyl umbelliferyl-ß-D-glucuronide (MUG). Discs are added to LST inoculated with selected dilutions of samples. Samples are incubated at 35–37 °C and examined after 24 and 48 ±2 h for confirmed total coliforms and after 30 ±2 h for confirmed E. coli results. ß-Galactosidase, from coliforms present in samples, cleaves X-Gal into 5-bromo-4-chloro-indoxyl intermediate which undergoes oxidation to yield water-insoluble blue dimer, visually detectable on disc or in surrounding medium as confirmed positive result for total coliform activity. ß-Glucuronidase, from E. coli present in samples, cleaves MUG into glucuronide and methyl umbelliferone which fluoresces under long wave UV light (366 nm) as confirmed positive result for E. coli presence.NOTE : As E. coli O157:H7 does not produce ß-glucuronidase, ColiComplete ® is not suitable for the detection of E. coli O157:H7.A. Sample PreparationPrepare appropriate serial dilutions as indicated in FDA Bacteriological Analytical Manual (BAM), or AOAC Official Methods of Analysis according to sample type.B. InoculationInoculate LST tubes with appropriate sample dilution series selected to determine MPN levels or presence/absence of total coliforms and E. coli in sample. Aseptically add a single ColiComplete ® disc to each tube. Incubate at 35–37 °C.C. Reading ColiComplete ®a. For total coliforms — After at least 24 h incubation, examine each tube for visually detectable blue color on disc or in surrounding medium. Presence of blue color indicates confirmed positive result for total coliforms.NOTE: A wide range of blue color intensity may be expected, depending on sample composition and microflora. All blue reactions are positive regardless of intensity of color.Reincubate at 35–37 °C. After additional 24 ±2 h re-examine. Continued absence of blue indicates negative result; presence of blue indicates confirmed positive result for total coliforms. Read and record the MPN code or presence/absence of total coliforms in the sample.b. For E.coli — After 30 ±2 h from start of initial incubation, examine tubes under long-wave UV light (366 nm). Fluorescent tubes indicate confirmed positive result for E. coli. Read and record the MPN code or presence/absence of E. coli in the sample.D. CONTROLSPositive and negative controls should be used to facilitate interpretation of MUG fluorescent reaction. Use one known positive E. coli tube and two negative controls - one non -E. coli /coliform tube (e.g., Klebsiella spp.) and one uninoculated media tube.NOTE: Use borosilicate glass tubes, flint glass gives fluorescence that may be misinterpreted for a positive result.Lit. No. MK_UG4655EN Merck KGaAFrankfurter Strasse 25064293 DarmstadtGermanyPage 2 of 2 E. Method Modification for Certain JuicesApplicable to juice products/processors which rely on treatments that do not come into direct contact with all parts of the juice, as contained in 21 CFR Part 120: Rules and Regulations. Hazard Analysis and Critical Control Point (HAACP); Procedures for the Safe and Sanitary Processing and Importing of Juice; Final Rule. Vol 66 No. 13. 6137-6202. Use the modified method “Analysis for Escherichia coli in Citrus Juices - Modifi cation of AOAC Official Method 992.30” as stated in Section 120.25 (a).F. StorageStore unused discs at 2–8 °C (36–46 °F) in a sealed container, with desiccant.G. DisposalAfter use, all tubes must be steam-sterilized at 121 °C for at least 30 min before discarding. For in-vitro diagnostic use only.Manufacturing EntityBioControl Systems, Inc, 12822 SE 32nd St, Bellevue, WA 98005, USA.BioControl Systems, Inc is an affiliate of Merck KGaA, Darmstadt, Germany.。

BACGro Sabouraud Dextrose Agar (SDA) 产品说明书

BACGro Sabouraud Dextrose Agar (SDA) 产品说明书

Sabouraud Dextrose Agar - Instructions for UseIntended UseBAC Gro TM Sabouraud Dextrose Agar (SDA), when prepared as directed, is intended for use for the culture and isolation of yeasts and molds. Sabouraud Dextrose Agar is not intended for use in diagnosis, treatment, or prevention of disease in humans. BAC Gro TM Sabouraud Dextrose Agar conforms to harmonized USP/EP/JP requirements1-3.Product SummarySabouraud Dextrose Agar is a general purpose medium used for the cultivation and isolation of a wide variety of yeasts and molds. The low pH promotes growth of these fungi while simultaneously being slightly inhibitory to competing bacteria that may be present in a sample. Further selectivity can be achieved through the addition of antibiotic supplements.The media includes peptone to provide nitrogen and vitamins for the yeast and mold. Dextrose is included at a very high concentration to provide a carbon source for energy. Agar serves as the solidifying agent.Formulation* (per Liter)Peptone 10.0 gDextrose 40.0 gAgar 15.0 gTotal 65.0 g/L*Formula may be supplemented and/or adjusted as required to meet performance criteriaNote: Sabouraud Dextrose Agar with Chloramphenicol is also available, containing chloramphenicol at 100mg per LiterDirections1.Add 65.0 g of Sabouraud Dextrose Agar powder to 1L purified water.2.Heat and agitate to form aqueous solution.3.Autoclave at 121 degrees Celsius for 15 minutes.4.Cool prior to use.PrecautionsThis product is for laboratory use only and should only be used by qualified, trained laboratory personnel. Personnel should always use proper aseptic technique and observe all biohazardous precautions. All microbiological cultures should be presumed to be infectious.Avoid ingestion, inhalation, or contact with skin and mucous membranes. If contact occurs, flush the area with clean water.Quality Control SpecificationsGold Standard Diagnostics tests each lot of manufactured BAC Gro TM culture media utilizing appropriate control organisms and specifications as documented on the Certificate of Analysis. End users should perform quality control testing in accordance with government regulatory requirements and accreditation guidelines. The following specifications are routinely used for testing:Appearance (dehydrated): Light beige, homogenous, free flowing powder, free of debris Appearance (prepared): Clear to hazy, amber, with no precipitate or debrispH (prepared): 5.4 – 5.8 at 25°COrganism Performance:Limitations of the ProcedureThis product is not labeled for use as a medical device, and is not intended to diagnose, treat, or prevent disease.Due to variation in nutritional requirements, some strains may be encountered that grow poorly in this medium.Antimicrobial agents that are added to a medium may inhibit the growth of fungal pathogens.Acidic media should avoid being overheated; this will result in a softer mediumStorage and ExpirationBAC Gro TM Sabouraud Dextrose Agar should be stored at 2 – 30 degrees Celsius. Because of the hygroscopic nature of dehydrated culture media, it should be stored in a dry place and the lid should remain tightly sealed. Media should be discarded if it is not free flowing or shows discoloration.The expiration date printed on the label is applicable to media stored as directed.Catalog NumbersDCM3701 – Sabouraud Dextrose Agar, 500gDCM3710 – Sabouraud Dextrose Agar, 10 kgDCM3805 – Sabouraud Dextrose Agar with Chloramphenicol, 5kgDCM3810 – Sabouraud Dextrose Agar with Chloramphenicol, 10kg1 United States Pharmacopeial Convention. United States Pharmacopoeia and National Formulary (USP-NF).2 Directorate for the Quality of Medicines and the Council of Europe. The European Pharmacopoeia.3 Pharmaceuticals and Medical Devices Agency, Ministry of Health, Labor, and Welfare. Japanese Pharmacopoeia.。

整理卡格净列说明书_附件

整理卡格净列说明书_附件

附件192个药物临床试验数据自查核查注册申请清单附件1食品中二甲双胍等非食品用化学物质的测定BJS 201901•范围本标准规定了食品(含特殊食品)中二甲双胍、苯乙双胍、丁二胍、伏格列波糖、阿卡波糖、维达列汀、罗格列酮、西他列汀、吡格列酮、氯磺丙脲、达格列净、格列吡嗪、甲苯磺丁脲、醋磺己脲、妥拉磺脲、瑞格列奈、卡格列净、格列齐特、格列波脲、格列本脲、那格列奈、格列美脲、曲格列酮、格列喹酮、莫格他唑、GW501516、环格列酮等27种非食品用化学物质的高效液相色谱-串联质谱测定方法。

本标准适用于茶叶、奶粉、饼干、酒、饮料等食品(包括上述类似基质的片剂、胶囊剂等形式的特殊食品)中二甲双胍等27种非食品用化学物质的测定。

•原理试样粉碎后经甲醇超声提取,过滤后,上清液供高效液相色谱-串联质谱测定,外标法定量。

•试剂和材料除另有规定,本方法所用试剂均为分析纯或以上规格,水为GB/T 6682规定的一级水。

3.1 试剂3.1.1 乙腈(CH3CN):色谱纯。

3.1.2 甲酸(HCOOH):色谱纯。

3.1.3 甲酸铵(HCOONH4):色谱纯。

3.1.4 甲醇(CH3OH):分析纯。

3.2溶液配制3.2.1 0.1%甲酸水溶液:量取甲酸(3.1.2)1 mL,用水稀释至1000 mL,用滤膜(4.2)过滤后备用。

3.2.2 5 mmol/L甲酸铵水溶液:称取甲酸铵(3.1.3)0.315 g,用水稀释至1000 mL,用滤膜(4.2)过滤后备用。

3.2.3 5 mmol/L甲酸铵乙腈溶液:称取甲酸铵(3.1.3)0.315 g,加水50 mL溶解后,用乙腈稀释至1000 mL,用滤膜(4.2)过滤后备用。

3.3标准品苯乙双胍、丁二胍、二甲双胍、伏格列波糖、阿卡波糖、维达列汀、罗格列酮、西他列汀、吡格列酮、氯磺丙脲、达格列净、格列吡嗪、甲苯磺丁脲、醋磺己脲、妥拉磺脲、瑞格列奈、卡格列净、格列齐特、格列波脲、格列本脲、那格列奈、格列美脲、曲格列酮、格列喹酮、莫格他唑、GW501516、环格列酮标准品的中文名称、英文名称、CAS登录号、分子式、相对分子质量详见附录A中的表A.1,各标准品纯度均≥95%。

Jevtana 和 Cabazitaxel 产品说明书

Jevtana 和 Cabazitaxel 产品说明书

Cabazitaxel:Jevtana®; Cabazitaxel§(Intravenous)Document Number: IC‐0074 Last Review Date: 02/02/2023Date of Origin: 01/2012Dates Reviewed: 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014,09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017,05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 04/2019, 04/2020, 04/2021, 04/2022, 02/2023I.Length of AuthorizationCoverage will be provided for 6 months and may be renewed.II.Dosing LimitsA.Quantity Limit (max daily dose) [NDC unit]:-Jevtana 60 mg solution for injection, single-dose vial: 1 vial per 21 day supply-Cabazitaxel 45 mg/4.5 mL solution for injection, multiple-dose vial: 1 vial per 21 day supply-Cabazitaxel 60 mg/6 mL solution for injection, multiple-dose vial: 1 vial per 21 day supplyB.Max Units (per dose and over time) [HCPCS Unit]:-Jevtana: 60 billable units per 21 days-Cabazitaxel: 50 mg per 21 daysIII.Initial Approval Criteria 1,2Coverage is provided in the following conditions:∙Patient is at least 18 years of age; ANDUniversal Criteria 1-4∙Must be used in combination with a steroid (e.g. prednisone or dexamethasone); AND∙Patient does not have severe hepatic impairment (e.g., total bilirubin > 3 times the upper limit of normal); ANDProstate Cancer † 1-4∙Patient has castration-resistant metastatic adenocarcinoma; ANDo Used as a single agent †; AND▪Patient must have been previously treated with docetaxel unless not a candidate for or intolerant to docetaxel; ORo Used in combination with carboplatin ‡; AND▪Used for fit patients with aggressive variant disease (e.g., visceral metastases, low prostate-specific antigen and bulky disease, high LDH, high CEA, lytic bonemetastases, neuroendocrine prostate cancer histology) or unfavorable genomics(e.g., defects in at least two of the following: PTEN, TP53, and RB1); ANDPatient has received prior docetaxel and no prior novel hormone therapy(e.g., abiraterone, enzalutamide, darolutamide, apalutamide, etc.); ORPatient has received prior novel hormone therapy and no prior docetaxel; ORPatient has received prior docetaxel and prior novel hormone therapy; AND -Patient does not have visceral metastases; OR∙Patient has castration-resistant metastatic small cell/neuroendocrine prostate cancer;ANDo Used in combination with carboplatin; ANDo Used for fit patients with aggressive variant disease (e.g., visceral metastases, low prostate-specific antigen and bulky disease, high LDH, high CEA, lytic bonemetastases, neuroendocrine prostate cancer histology) or unfavorable genomics (e.g.,defects in at least two of the following: PTEN, TP53, and RB1)† FDA Approved Indication(s); ‡ Compendia recommended indication(s); Ф Orphan DrugIV.Renewal Criteria 1,2Coverage can be renewed based upon the following criteria:∙Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performancestatus, etc. identified in section III; AND∙Disease response with treatment as defined by lack of disease progression, improvement in tumor size and/or improvement in patient symptoms; AND∙Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: bone marrow suppression (neutropenia, anemia, thrombocytopenia, and/or pancytopenia), severe hypersensitivity reactions, gastrointestinal adverse reactions (severe diarrhea,nausea, vomiting), urinary disorders including severe hemorrhagic cystitis, renal failure,hepatic impairment, respiratory disorders (interstitial pneumonia/pneumonitis, interstitial lung disease, acute respiratory distress syndrome), etc.V.Dosage/Administration 1,2Prostate Cancer JevtanaAdminister 20-25 mg/m², intravenously, every 3 weeks in combination with an oral corticosteroidCabazitaxelAdminister 20 mg/m², intravenously, every 3 weeks in combination with an oral corticosteroidVI.Billing Code/Availability InformationHCPCS code:∙J9043 – Injection, cabazitaxel, 1 mg: 1 billable unit= 1 mg (Jevtana ONLY)∙J9999 – Not otherwise classified, antineoplastic drugs (Cabazitaxel ONLY)NDC:∙Jevtana 60 mg/1.5 mL solution for injection, single-dose vial: 00024-5824-xx∙Cabazitaxel 45 mg/4.5 mL solution for injection, multiple-dose vial: 00781-3186-xx §∙Cabazitaxel 60 mg/6 mL solution for injection, multiple-dose vial: 00781-3193-xx §§ Designated products approved by the FDA as a 505(b)(2) NDA of the innovator product. These products are not rated as therapeutically equivalent to their reference listed drug in the Food and Drug Administration’s (FDA) Orange Book and are therefore considered single source products based on the statutory definition of “single source drug” in section 1847A(c)(6) of the Act. For a complete list of all approved 505(b)(2) NDA products please reference the latest edition of the Orange Book:Approved Drug Products with Therapeutic Equivalence Evaluations | Orange Book | FDAVII.References1.Jevtana [package insert]. Bridgewater, NJ; Sanofi-Aventis U.S. LLC; February 2021.Accessed January 2023.2.Cabazitaxel [package insert]. Princeton, NJ; Sandoz Inc.; January 2023. Accessed January20233.Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCNCompendium®) for cabazitaxel. National Comprehensive Cancer Network, 2023. TheNCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONALCOMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® aretrademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to . Accessed January 2023.4.Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCNCompendium®) for Prostate Cancer 1.2023. National Comprehensive Cancer Network,2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®.NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCNGUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to. Accessed January 2023.5.Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and CytotoxicAnticancer Agents: A Position Statement of the Hematology/Oncology PharmacyAssociation. J Oncol Pract. 2018 Mar;14(3):e130-e136.6.de Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone pluscabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010. Oct2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.7.Sartor AO, Oudard S, Sengelov L, et al. Cabazitaxel vs docetaxel in chemotherapy-naive(CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). Journal of Clinical Oncology34, no. 15_suppl(May 20,2016)5006-5006. DOI: 10.1200/JCO.2016.34.15_suppl.5006.8.Fizazi K, Kramer G, Eymard JC, et al. Quality of life in patients with metastatic prostatecancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of randomized multicentre, open-label, phase 4 study. Lancet Oncol. 2020Nov;21(11):1513-1525. doi: 10.1016/S1470-2045(20)30449-6.9.Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III Study Comparing a ReducedDose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) inPostdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017 Oct 1;35(28):3198-3206. doi: 10.1200/JCO.2016.72.1076. Appendix 1 – Covered Diagnosis Codes1010C61 Malignant neoplasm of prostateC7A.1 Malignant poorly differentiated neuroendocrine tumorsC7A.8 Other malignant neuroendocrine tumorsAppendix 2 – Centers for Medicare and Medicaid Services (CMS)Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs) and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: https:///medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/AJurisdiction Applicable State/US Territory ContractorE (1) CA, HI, NV, AS, GU, CNMI Noridian Healthcare Solutions, LLCF (2 & 3) AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ Noridian Healthcare Solutions, LLC5 KS, NE, IA, MO Wisconsin Physicians Service Insurance Corp (WPS)6 MN, WI, IL National Government Services, Inc. (NGS)H (4 & 7) LA, AR, MS, TX, OK, CO, NM Novitas Solutions, Inc.8 MI, IN Wisconsin Physicians Service Insurance Corp (WPS) N (9) FL, PR, VI First Coast Service Options, Inc.J (10) TN, GA, AL Palmetto GBA, LLCM (11) NC, SC, WV, VA (excluding below) Palmetto GBA, LLCNovitas Solutions, Inc.L (12) DE, MD, PA, NJ, DC (includes Arlington &Fairfax counties and the city of Alexandria in VA)K (13 & 14) NY, CT, MA, RI, VT, ME, NH National Government Services, Inc. (NGS)15 KY, OH CGS Administrators, LLC。

坎格列净片说明书简化版

坎格列净片说明书简化版
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
Revised: XX/2013
8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 8.7 Hepatic Impairment
! Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA (5.4)
10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of
------------------------------ADVERSE REACTIONS------------------------------! Most common adverse reactions associated with INVOKANA (5% or
greater incidence): female genital mycotic infections, urinary tract infection, and increased urination (6.1)
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

卡格净列说明书整理表姓名:职业工种:申请级别:受理机构:填报日期:附件1食品中二甲双胍等非食品用化学物质的测定BJS 2019011.范围本标准规定了食品(含特殊食品)中二甲双胍、苯乙双胍、丁二胍、伏格列波糖、阿卡波糖、维达列汀、罗格列酮、西他列汀、吡格列酮、氯磺丙脲、达格列净、格列吡嗪、甲苯磺丁脲、醋磺己脲、妥拉磺脲、瑞格列奈、卡格列净、格列齐特、格列波脲、格列本脲、那格列奈、格列美脲、曲格列酮、格列喹酮、莫格他唑、GW501516、环格列酮等27种非食品用化学物质的高效液相色谱-串联质谱测定方法。

本标准适用于茶叶、奶粉、饼干、酒、饮料等食品(包括上述类似基质的片剂、胶囊剂等形式的特殊食品)中二甲双胍等27种非食品用化学物质的测定。

2.原理试样粉碎后经甲醇超声提取,过滤后,上清液供高效液相色谱-串联质谱测定,外标法定量。

3.试剂和材料除另有规定,本方法所用试剂均为分析纯或以上规格,水为GB/T 6682规定的一级水。

3.1 试剂3.1.1 乙腈(CH3CN):色谱纯。

3.1.2 甲酸(HCOOH):色谱纯。

3.1.3 甲酸铵(HCOONH4):色谱纯。

3.1.4 甲醇(CH3OH):分析纯。

3.2溶液配制3.2.1 0.1%甲酸水溶液:量取甲酸(3.1.2)1 mL,用水稀释至1000 mL,用滤膜(4.2)过滤后备用。

3.2.2 5 mmol/L甲酸铵水溶液:称取甲酸铵(3.1.3)0.315 g,用水稀释至1000 mL,用滤膜(4.2)过滤后备用。

3.2.3 5 mmol/L甲酸铵乙腈溶液:称取甲酸铵(3.1.3)0.315 g,加水50 mL溶解后,用乙腈稀释至1000 mL,用滤膜(4.2)过滤后备用。

3.3标准品苯乙双胍、丁二胍、二甲双胍、伏格列波糖、阿卡波糖、维达列汀、罗格列酮、西他列汀、吡格列酮、氯磺丙脲、达格列净、格列吡嗪、甲苯磺丁脲、醋磺己脲、妥拉磺脲、瑞格列奈、卡格列净、格列齐特、格列波脲、格列本脲、那格列奈、格列美脲、曲格列酮、格列喹酮、莫格他唑、GW501516、环格列酮标准品的中文名称、英文名称、CAS登录号、分子式、相对分子质量详见附录A中的表A.1,各标准品纯度均≥95%。

3.4标准溶液的配制3.4.1 标准储备液(5 mg/mL):准确称取伏格列波糖、阿卡波糖、达格列净、卡格列净、曲格列酮、环格列酮各标准品(3.3)50.0 mg(精确至0.0001 g),分别置于10 mL容量瓶中,用甲醇(3.1.4)溶解并稀释至刻度,摇匀,制成浓度为5 mg/mL标准储备液A,-20℃保存,有效期3个月。

3.4.2标准储备液(100 μg/mL):准确称取苯乙双胍、丁二胍、二甲双胍、维达列汀、罗格列酮、西他列汀、吡格列酮、氯磺丙脲、格列吡嗪、甲苯磺丁脲、醋磺己脲、妥拉磺脲、瑞格列奈、格列齐特、格列波脲、格列本脲、那格列奈、格列美脲、格列喹酮、莫格他唑、GW501516各标准品(3.3)10.0 mg(精确至0.0001 g),分别置于100 mL容量瓶中,用甲醇(3.1.4)溶解并稀释至刻度,摇匀,制成浓度为100 μg/mL标准储备液B,-20 ℃保存,有效期3个月。

3.4.3混合标准中间液A:分别准确吸取伏格列波糖和阿卡波糖的标准储备液(3.4.1)及苯乙双胍、丁二胍、二甲双胍的标准储备液(3.4.2)各1 mL,置于同一100mL容量瓶中,用甲醇(3.1.4)稀释至刻度,摇匀,制成混合标准中间液(A),其中伏格列波糖和阿卡波糖浓度为50 μg/mL,苯乙双胍、丁二胍、二甲双胍浓度为1 μg/mL。

3.4.4混合标准中间液B:分别准确吸取达格列净、卡格列净、曲格列酮、环格列酮的标准储备液(3.4.1)各1 mL及维达列汀、罗格列酮、西他列汀、吡格列酮、氯磺丙脲、格列吡嗪、甲苯磺丁脲、醋磺己脲、妥拉磺脲、瑞格列奈、格列齐特、格列波脲、格列本脲、那格列奈、格列美脲、格列喹酮、莫格他唑、GW501516的标准储备液(3.4.2)各1 mL,置于同一100 mL容量瓶中,用甲醇(3.1.4)稀释至刻度,摇匀,制成混合标准中间液B,其中达格列净、卡格列净、曲格列酮、环格列酮浓度为50 μg/mL,维达列汀等18个化合物浓度为1 μg/mL。

3.4.5 混合标准工作溶液A:分别准确吸取混合标准中间液A(3.4.3)各0.1 mL、0.2 mL、0.4 mL、1.0 mL、2.0 mL,置于20 mL容量瓶中,用甲醇(3.1.4)稀释至刻度,摇匀,作为系列标准工作溶液S1~S5,伏格列波糖和阿卡波糖的浓度均依次为0.25 μg/mL、0.5 μg/mL、1.0 μg/mL、2.5 μg/mL、5.0 μg/mL;苯乙双胍、丁二胍、二甲双胍的浓度均依次为5 ng/mL、10 ng/mL、20 ng/mL、50 ng/mL、100 ng/mL。

3.4.6混合标准工作溶液B:分别准确吸取混合标准中间液B(3.4.4)各0.1 mL、0.2 mL、0.4 mL、1.0 mL、2.0 mL,置于20 mL容量瓶中,用甲醇(3.1.4)稀释至刻度,摇匀,作为系列标准工作溶液S(1)~S(5),达格列净、卡格列净、曲格列酮、环格列酮4个化合物的浓度均依次为0.25 μg/mL、0.5 μg/mL、1.0 μg/mL、2.5 μg/mL、5.0 μg/mL;维达列汀等18个化合物浓度均依次为5 ng/mL、10 ng/mL、20 ng/mL、50 ng/mL、100 ng/mL。

4.仪器和设备4.1高效液相色谱-串联质谱仪,配有电喷雾(ESI)离子源。

4.2分析天平:感量0.0001g。

4.3超声波水浴。

5.分析步骤5.1试样的制备5.1.1茶叶、奶粉、饼干、片剂、胶囊取适量研细,称取粉末1 g(精确至0.0001 g)置于50 mL量瓶中,加入甲醇(3.1.4)45 mL,振摇,超声提取10 min,放冷,加甲醇(3.1.4)定容至刻度,摇匀,用滤膜(0.22 µm,有机相型)过滤,取续滤液,可根据实际浓度适当稀释至线性范围内,供液相色谱-质谱联用仪分析。

5.1.2 饮料、口服液准确吸取1 mL,置50 mL量瓶中,加入甲醇(3.1.4)45 mL,振摇,超声提取10 min,放冷,加甲醇(3.1.4)定容至刻度,摇匀,用滤膜(0.22 µm,有机相型)过滤,取续滤液,可根据实际浓度适当稀释至线性范围内,供液相色谱-质谱联用仪分析。

5.1.3酒准确吸取1 mL,置蒸发皿中,水浴蒸至无醇味,用适量甲醇(3.1.4)溶解并转移至50 mL 量瓶中,振摇,超声提取10 min,放冷,加甲醇(3.1.4)定容至刻度,摇匀,用滤膜(0.22 µm,有机相型)过滤,取续滤液,可根据实际浓度适当稀释至线性范围内,供液相色谱-质谱联用仪分析。

5.2 仪器参考条件5.2.1 色谱条件5.2.1.1 系统1(测定苯乙双胍、丁二胍、二甲双胍、伏格列波糖、阿卡波糖)a) 色谱柱:酰胺基键合杂化颗粒色谱柱(2.1×100 mm,3.5 µm),或性能相当者;b)流动相:A为含5 mmol/L的甲酸铵溶液(3.2.2),B为5 mmol/L甲酸铵乙腈溶液(3.2.3),梯度洗脱程序见表2;c)流速:300 μL/min;d) 柱温:70℃;e) 进样量:1 μL。

5.2.1.2 系统2(测定维达列汀、罗格列酮、西他列汀、吡格列酮、氯磺丙脲、达格列净、格列吡嗪、甲苯磺丁脲、醋磺己脲、妥拉磺脲、瑞格列奈、卡格列净、格列齐特、格列波脲、格列本脲、那格列奈、格列美脲、曲格列酮、格列喹酮、莫格他唑、GW501516、环格列酮)a) 色谱柱:亲水三键键合相实心核颗粒色谱柱(2.1×100 mm,2.7 µm),或性能相当者;b)流动相:A为含0.1%甲酸水溶液(3.2.1),B为乙腈(3.1.1),梯度洗脱程序见表3;c)流速:300μL/min;d) 柱温:30℃;e) 进样量:1μL。

5.2.2 质谱条件a) 离子源:电喷雾离子源(ESI源)。

b) 检测方式:多反应监测(MRM)。

c) 扫描模式:正离子模式或负离子模式。

d)干燥气、雾化气、鞘气、碰撞气等均为高纯氮气或其他合适气体,使用前应调节相应参数使质谱灵敏度达到检测要求,毛细管电压、干燥气温度、鞘气温度、鞘气流量、喷嘴电压、碰撞能量、碎裂电压等参数应优化至最佳灵敏度,监测离子对和定量离子对等信息详见附录A。

5.3 定性测定按照高效液相色谱-串联质谱条件测定试样和标准工作溶液,记录试样和标准溶液中各化合物的色谱保留时间,以相对于最强离子丰度的百分比作为定性离子对的相对丰度,记录浓度相当的试样与标准工作溶液中相应成分的相对离子丰度。

当试样中检出与27种化合物中某标准品色谱峰保留时间一致的色谱峰(变化范围在±2.5%之内),并且相对离子丰度允许偏差不超过表4规定的范围,可以确定试样中检出相应化合物。

5.4定量测定5.4.1标准曲线的制作将混合标准工作溶液A(3.4.5)分别按仪器参考条件(5.2.1.1和5.2.2)进行测定,将混合标准工作溶液B(3.4.6)分别按仪器参考条件(5.2.1.2和5.2.2)进行测定,得到相应的标准溶液的色谱峰面积。

以混合标准工作溶液的浓度为横坐标,以色谱峰的峰面积为纵坐标,绘制标准曲线。

5.4.2试样溶液的测定将试样溶液(5.1)按仪器参考条件(5.2)进行测定,得到相应的样品溶液的色谱峰面积。

根据标准曲线得到待测液中组分的浓度,平行测定次数不少于两次。

6.空白试验除不加试样外,均按试样同法操作。

7.结果计算将液相色谱-质谱测得浓度代入下式计算含量: (1)式中:X — 试样中各待测物的含量,单位为毫克每千克(mg/kg);c — 从标准曲线中读出的供试品溶液中各待测物的浓度,单位为纳克每毫升(ng/mL);V — 样液最终定容体积,单位为毫升(mL);m —试样溶液所代表的质量,单位为克(g);K— 稀释倍数。

计算结果以重复性条件下获得的两次独立测定结果的算术平均值表示,结果保留三位有效数字。

8.检测方法的灵敏度、精密度、专属性8.1 灵敏度固体和液体取样量为1 g或1 mL,定容体积为50 mL时,伏格列波糖、阿卡波糖、达格列净、卡格列净、曲格列酮、环格列酮的定量限为12.5 mg/kg或12.5 mg/L;苯乙双胍、丁二胍、二甲双胍、维达列汀、罗格列酮、西他列汀、吡格列酮、氯磺丙脲、达格列净、格列吡嗪、甲苯磺丁脲、醋磺己脲、妥拉磺脲、瑞格列奈、卡格列净、格列齐特、格列波脲、格列本脲、那格列奈、格列美脲、曲格列酮、格列喹酮、莫格他唑、GW501516、环格列酮的定量限为0.25 mg/kg 或0.25 mg/L。

相关文档
最新文档